The results found that 93% of individuals in the high-risk group presented persistently positive antiphospholipid antibodies, compared with 47% of individuals in the lower-risk group.
Investigators found that positive antiphospholipid antibodies and traditional risk factors were associated with atherosclerotic cardiovascular disease.
At 16 weeks, patients treated with bimekizumab reported greater improvements in both mean spine pain and morning stiffness when compared with placebo. These improvements continued through week 52.